Ayunova Pharmaceutical LLP

Insulin (Various Types) for Injection BP

Insulin (Various Types) for Injection BP is a sterile parenteral preparation used for the effective management of diabetes mellitus. It contains insulin preparations designed to regulate blood glucose levels by facilitating cellular uptake of glucose and maintaining metabolic balance.

The product is available in Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, and Pre-Mixed Insulin formulations, making it suitable for individualized diabetic treatment plans in hospital and clinical settings.

Excipients: Glycerol, zinc chloride, metacresol / phenol, sodium hydroxide or hydrochloric acid for pH adjustment, and water for injection BP (varies by type).

• Management of Type 1 Diabetes Mellitus

• Management of Type 2 Diabetes Mellitus requiring insulin

• Control of hyperglycemia

• Use in hospitalized and critically ill patients

• Prevention of long-term diabetic complications

• Administered by subcutaneous injection

• Intravenous use only for specific insulin types under medical supervision

• Dosage depends on blood glucose levels, diet, body weight, and patient condition

• To be used strictly as prescribed by a healthcare professional

• Glass vials: 10 mL

• Prefilled insulin pens: 3 mL

• Cartridge systems (where applicable)

• Bulk hospital and institutional supply available

• Store at 2–8°C (Refrigerated)

• Do not freeze

• Protect from direct light

• Once opened, may be stored below 30°C for up to 28 days (as per insulin type)

• Pharmacopoeia: BP (British Pharmacopoeia)

• Shelf Life: Usually 24 months

• Manufacturing Standards: WHO-GMP certified

• Usage Area: Hospitals, clinics, diabetic care centers

• Prescription Status: Prescription drug (Rx)

Insulin (Human/Analog) Pre-Filled Syringe (PFS) 100 IU/ml

Insulin (Human/Analog) PFS 100 IU/ml is a sterile, ready-to-use injectable formulation designed for the management of diabetes mellitus. This formulation provides precise and consistent dosing to maintain optimal blood glucose levels. Human insulin mimics natural insulin produced by the pancreas, while insulin analogs offer rapid or prolonged action depending on the type. Pre-filled syringes (PFS) ensure ease of use, accuracy, and convenience for both patients and healthcare providers.

• Insulin (Human/Analog): 100 IU/ml

• Excipients: Water for injection, zinc, glycerol, phenol or metacresol (as preservative), and pH stabilizers

Available types: Rapid-acting, Short-acting, Intermediate-acting, Long-acting, and Mixed insulin analogs

• Management of type 1 and type 2 diabetes mellitus

• Control of hyperglycemia in patients with diabetes

• Can be used in insulin pumps or for subcutaneous injection therapy

• Suitable for intensive insulin therapy requiring precise dosing

• Administered subcutaneously or via insulin pen as per physician guidance

• Dosage individualized based on patient’s blood glucose levels, diet, and lifestyle

• PFS ensures accurate and convenient dosing without the need for drawing insulin from a vial

• Pre-filled syringe for accurate and ready-to-use administration

• Sterile, pyrogen-free, and BP/USP-compliant formulation

• Available in various action profiles (rapid, short, intermediate, long-acting)

• Supports precise diabetes management and improved patient compliance

• 1 ml PFS containing 100 IU insulin

• Available in single or multi-packs suitable for patient use

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light and moisture

• Keep out of reach of children

Metformin Tablets BP – 1000 mg

Metformin Tablets BP is an oral antihyperglycemic agent belonging to the biguanide class, used primarily in the management of type 2 diabetes mellitus. It helps control blood sugar levels by improving insulin sensitivity, reducing hepatic glucose production, and enhancing peripheral glucose uptake.

Metformin is widely recommended as first-line therapy for type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents, to achieve optimal glycemic control and reduce the risk of diabetes-related complications.

Each film-coated tablet contains:

• Metformin Hydrochloride BP – 1000 mg

• Excipients: q.s.

• Type 2 diabetes mellitus (T2DM)

• Glycemic control in overweight or obese patients with T2DM

• Prevention of type 2 diabetes in high-risk individuals (prediabetes)

• Polycystic ovary syndrome (PCOS) – to improve insulin sensitivity and regulate menstrual cycles

• Gestational diabetes (as per specialist supervision)

• Metabolic syndrome – as part of comprehensive management

• Route: Oral

• Usual Dose: 500 mg–1000 mg twice daily, or as prescribed by a physician

• Administration: Take with meals to reduce gastrointestinal discomfort

⚠ Dose adjustment required in renal impairment
⚠ Monitor renal function and blood glucose regularly

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Glimepiride Tablets BP – 4 mg

Glimepiride Tablets BP is an oral antihyperglycemic agent from the sulfonylurea class, used for the management of type 2 diabetes mellitus (T2DM). It works by stimulating insulin secretion from pancreatic β-cells and improving peripheral insulin sensitivity, thereby helping in effective glycemic control.

Glimepiride is commonly prescribed as monotherapy or in combination with other antidiabetic agents including metformin, to achieve optimal blood sugar control in type 2 diabetes patients.

Each film-coated tablet contains:

• Glimepiride BP – 4 mg

• Excipients: q.s.

• Type 2 diabetes mellitus (T2DM)

• Glycemic control in patients inadequately controlled with diet and exercise alone

• Combination therapy with metformin or other oral antidiabetics

• Adjunct therapy in patients with insulin resistance

• Gestational diabetes (under specialist supervision, limited use)

• Route: Oral

• Usual Dose: 1–4 mg once daily, adjusted according to blood glucose and patient response

• Administration: Take with breakfast or first main meal to reduce risk of hypoglycemia

⚠ Monitor blood glucose regularly
⚠ Caution in renal or hepatic impairment
⚠ Risk of hypoglycemia, especially in elderly patients

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Sitagliptin Tablets BP – 100 mg

Sitagliptin Tablets BP is an oral antidiabetic agent belonging to the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class, used for the management of type 2 diabetes mellitus (T2DM).

Sitagliptin works by inhibiting DPP-4 enzyme, which increases incretin hormone levels, leading to enhanced insulin secretion and reduced glucagon release in a glucose-dependent manner. This results in improved glycemic control without significant risk of hypoglycemia.

It is commonly prescribed as monotherapy in patients who cannot tolerate metformin or in combination therapy with metformin, sulfonylureas, or other antidiabetic agents for optimal glycemic control.

Each film-coated tablet contains:

• Sitagliptin Phosphate Monohydrate BP – 100 mg (equivalent to Sitagliptin 100 mg)

• Excipients: q.s.

• Type 2 diabetes mellitus (T2DM)

• Glycemic control in adults inadequately controlled with diet and exercise

• Combination therapy with metformin, sulfonylureas, or insulin

• Prevention of diabetes-related complications as part of comprehensive management

• Adjunct therapy for insulin resistance (under physician supervision)

• Route: Oral

• Usual Dose: 100 mg once daily, adjusted by physician based on glycemic response

• Administration: Take with or without food

⚠ Dose adjustment required in renal impairment
⚠ Monitor blood glucose regularly
⚠ Lower risk of hypoglycemia compared to sulfonylureas

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Metformin + Glimepiride Tablets BP – 500 mg + 2 mg

Metformin + Glimepiride Tablets BP is an oral antidiabetic combination therapy used for the management of type 2 diabetes mellitus.

• Metformin (500 mg): A biguanide class antihyperglycemic that reduces hepatic glucose production, increases insulin sensitivity, and improves peripheral glucose uptake.

• Glimepiride (2 mg): A sulfonylurea class drug that stimulates pancreatic beta cells to release insulin, lowering blood glucose levels.

This combination is ideal for patients whose blood glucose is not adequately controlled with monotherapy, providing synergistic glucose-lowering effects.

Each film-coated tablet contains:

• Metformin Hydrochloride BP – 500 mg

• Glimepiride BP – 2 mg

• Excipients: q.s.

• Type 2 diabetes mellitus (adult patients)

• Combination therapy when monotherapy is insufficient

• Improvement of glycemic control in insulin-resistant patients

• Adjunct to diet and lifestyle modifications

• May help in reducing cardiovascular risk associated with diabetes

• Route: Oral

• Usual Dose: 1 tablet once or twice daily, as prescribed by the physician

• Administration: Take with meals to reduce gastrointestinal side effects

⚠ Monitor blood glucose regularly
⚠ Caution in patients with renal or hepatic impairment
⚠ Contraindicated in type 1 diabetes and during pregnancy

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Metformin + Sitagliptin Tablets BP – 500 mg + 50 mg

Metformin + Sitagliptin Tablets BP is an oral antidiabetic combination therapy used for the management of type 2 diabetes mellitus.

• Metformin (500 mg): A biguanide class antihyperglycemic that reduces hepatic glucose production, increases insulin sensitivity, and improves peripheral glucose uptake.

• Sitagliptin (50 mg): A DPP-4 inhibitor that enhances the incretin system, increasing insulin secretion and reducing glucagon levels, thereby controlling postprandial and fasting blood glucose.

This combination is ideal for patients inadequately controlled with metformin alone, offering effective glycemic control and a low risk of hypoglycemia.

Each film-coated tablet contains:

• Metformin Hydrochloride BP – 500 mg

• Sitagliptin Phosphate Monohydrate BP – 50 mg

• Excipients: q.s.

• Type 2 diabetes mellitus (adult patients)

• Combination therapy when monotherapy is insufficient

• Improvement of glycemic control in insulin-resistant patients

• Adjunct to diet and lifestyle modifications

• Management of both fasting and postprandial blood glucose levels

• Route: Oral

• Usual Dose: 1 tablet twice daily, or as prescribed by the physician

• Administration: Take with meals to reduce gastrointestinal side effects

⚠ Monitor blood glucose regularly
⚠ Caution in patients with renal or hepatic impairment
⚠ Contraindicated in type 1 diabetes and during pregnancy

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Metformin + Vildagliptin Tablets BP – 500 mg + 50 mg

Metformin + Vildagliptin Tablets BP is an oral antidiabetic combination therapy designed for the management of type 2 diabetes mellitus.

• Metformin (500 mg): A biguanide class antihyperglycemic that reduces hepatic glucose production, enhances insulin sensitivity, and improves peripheral glucose uptake.

• Vildagliptin (50 mg): A DPP-4 inhibitor that enhances incretin hormone activity, increases insulin secretion, and suppresses glucagon release, effectively controlling both fasting and postprandial blood glucose.

This combination is ideal for patients inadequately controlled with monotherapy, providing effective glycemic control with low risk of hypoglycemia.

Each film-coated tablet contains:

• Metformin Hydrochloride BP – 500 mg

• Vildagliptin BP – 50 mg

• Excipients: q.s.

• Type 2 diabetes mellitus (adult patients)

• Combination therapy when monotherapy is insufficient

• Improvement of glycemic control in insulin-resistant patients

• Adjunct to diet and lifestyle modifications

• Management of both fasting and postprandial blood glucose levels

• Route: Oral

• Usual Dose: 1 tablet twice daily, or as prescribed by the physician

• Administration: Take with meals to reduce gastrointestinal side effects

⚠ Monitor blood glucose regularly
⚠ Caution in patients with renal or hepatic impairment
⚠ Contraindicated in type 1 diabetes and during pregnancy

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Metformin + Pioglitazone Tablets BP – 500 mg + 15 mg

Metformin + Pioglitazone Tablets BP is an oral antidiabetic combination therapy used for the management of type 2 diabetes mellitus.

• Metformin (500 mg): A biguanide class antihyperglycemic that reduces hepatic glucose production, enhances insulin sensitivity, and improves peripheral glucose uptake.

• Pioglitazone (15 mg): A thiazolidinedione class drug that activates PPAR-γ receptors, improving insulin sensitivity in muscle and adipose tissue and lowering blood glucose levels.

This combination is ideal for patients inadequately controlled with monotherapy, providing synergistic effects for effective glycemic control.

Each film-coated tablet contains:

• Metformin Hydrochloride BP – 500 mg

• Pioglitazone Hydrochloride BP – 15 mg

• Excipients: q.s.

• Type 2 diabetes mellitus (adult patients)

• Combination therapy when monotherapy is insufficient

• Improvement of glycemic control in insulin-resistant patients

• Adjunct to diet and lifestyle modifications

• Management of both fasting and postprandial blood glucose levels

• Route: Oral

• Usual Dose: 1 tablet once or twice daily, or as prescribed by the physician

• Administration: Take with meals to reduce gastrointestinal side effects

⚠ Monitor blood glucose, liver function, and weight regularly
⚠ Caution in patients with heart failure or hepatic impairment
⚠ Contraindicated in type 1 diabetes and during pregnancy

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Metformin Hydrochloride Prolonged Release 500 mg + Glimepiride 1 mg Tablets IP is a combination oral antidiabetic medication used in the management of type 2 diabetes mellitus. Metformin helps reduce hepatic glucose production and improves insulin sensitivity, while Glimepiride stimulates insulin secretion from the pancreas. The prolonged-release formulation of Metformin ensures sustained glucose control with reduced gastrointestinal side effects. This medication should be used under the supervision of a qualified physician.

• Active Ingredients:

  • Metformin Hydrochloride (Prolonged Release) – 500 mg

  • Glimepiride – 1 mg

• Excipients:
  q.s.

• Dosage Form:
  Film-coated tablets

This combination tablet is indicated for:

• Management of type 2 diabetes mellitus in patients not adequately controlled with diet and exercise alone

• Patients requiring dual therapy for better glycemic control

(Prescription medicine – use only under medical supervision)

• Dosage as directed by the treating physician

• Tablets should be swallowed whole with water, preferably after meals

• Do not crush or chew the tablets

• Regular monitoring of blood glucose levels is recommended

• Store below 30°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

• For prescription use only

• Not recommended during pregnancy or breastfeeding unless prescribed

• Monitor renal function and liver function during prolonged therapy

• Use with caution in patients with hepatic or renal impairment

• Strip or bottle packing (as available)

• Suitable for hospital and pharmacy supply

• Manufactured in compliance with IP and GMP guidelines

• Quality tested for safety, purity, and efficacy

• India